
Krsnaa Diagnostics Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Krsnaa Diagnostics targets a robust revenue growth with a CAGR of approximately 25%-30% over the next 2-5 years.
- FY’24 revenue was INR 620 crores with 27% YoY growth; strong momentum expected to continue.
- Expansion is focused on radiology and pathology, with a 60:40 radiology to pathology mix anticipated.
- New tenders and projects, especially in radiology (CT scans, MRIs), will drive incremental growth.
- B2C business is an emerging segment expected to grow steadily, starting from around 2%-3% of revenue.
- Mature PPP centers typically achieve higher margins and stable revenue growth after 3 years.
- Investments in infrastructure and new capabilities are expected to convert into higher volumes and stable EBITDA margins (~25%) as projects mature.
See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company aims to maintain existing debt levels around INR53 crores as of March 2024 and does not foresee significant increases in the near term.
- Debt discussed primarily relates to short-term working capital needs due to increased receivables and investment in capital expenditure (e.g., down payments on equipment).
- Management’s stance is to try to be debt-free but expects to maintain manageable debt levels given business growth dynamics.
- There is no explicit mention of any immediate or planned equity fundraising in the disclosed discussions.
- Future decisions on capital expenditure, such as in the event of winning the Rajasthan project, will dictate if incremental borrowing is needed.
- Some pay-per-use agreements initiated with partners aim to expand operations without heavy debt or asset commitments.
See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.
Capex plans
Yes- FY '25 and FY '26 capex is expected around INR 150 crores, excluding Rajasthan.
- If Rajasthan project comes through, capex could increase to around INR 250 crores (INR 50 crores incremental).
- Exact Rajasthan capex to be clarified once project details are finalized.
- Focus on asset-light model for B2C expansion, leveraging existing lab infrastructure with minimal incremental capex.
- Investments include setting up of new pathology labs and deployment of radiology equipment such as CT scans and MRIs.
- Maharashtra: 10 CT scans operationalized; 29 more to be operationalized soon with revenue expected from Q2 FY '25.
- Continuous investment in quality accreditations like CAP and expanding test menu.
- Plans to maintain debt levels to support capex and working capital needs without significant increase in overall debt.
Track Krsnaa Diagnostics — get its next earnings analysis in your feed
How does Krsnaa Diagnostics rank vs peers in Healthcare Services?
Pro featureHow does Krsnaa Diagnostics rank in Healthcare Services?
Compare Krsnaa Diagnostics against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.